By


Annovis Bio Enhances Leadership Team with Two Senior Appointments

Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory Operations

Company Promotes Cheng Fang, Ph.D., to Senior Vice President of Research & Development

See more here

By


VESTECK named “Top 10 Cardiovascular Device Company for 2021” by MedTech Outlook Magazine

See more here

By


Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401

See more here

By


Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry

– Manuscript further details findings from study assessing REL-1017 as adjunctive treatment for MDD

– Primary endpoint results included rapid, significant, and sustained efficacy vs. placebo 

– Safety analysis showed adverse event profile comparable to placebo, with no signs or symptoms of withdrawal or psychotomimetic effects associated with NMDAR blocking 

See more here

By


Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics

ANVS401 (Posiphen) Inhibits the Translation of mRNAs of Neurotoxic Proteins Responsible for the Progression of Neurodegenerative Diseases

See more here

By


ImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers

Clinical trials for ImmunoGenesis drug candidates to initiate in 2022

See more here

By


Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

See more here

By


Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

See more here

By


AllianceChicago to Offer Wellsheet’s Predictive Clinical Workflow Platform Integrated with athenahealth’s EHR 

Wellsheet Integration with athenaOne to Empower Primary Care Clinicians in Community Health Centers

See more here